Latest Contract Development And Manufacturing Organisation News

Page 3 of 3
Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.
Ada Torres
Ada Torres
31 Jan 2025

Browse the archive

Full archive